These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 25891226

  • 1. Discovery of microarray-identified genes associated with ovarian cancer progression.
    Liu X, Gao Y, Zhao B, Li X, Lu Y, Zhang J, Li D, Li L, Yin F.
    Int J Oncol; 2015; 46(6):2467-78. PubMed ID: 25891226
    [Abstract] [Full Text] [Related]

  • 2. Microarray-based identification of genes associated with cancer progression and prognosis in hepatocellular carcinoma.
    Yin F, Shu L, Liu X, Li T, Peng T, Nan Y, Li S, Zeng X, Qiu X.
    J Exp Clin Cancer Res; 2016 Aug 27; 35(1):127. PubMed ID: 27567667
    [Abstract] [Full Text] [Related]

  • 3. Screening for genes associated with ovarian cancer prognosis.
    Chang XH, Zhang L, Yang R, Feng J, Cheng YX, Cheng HY, Ye X, Fu TY, Cui H.
    Chin Med J (Engl); 2009 May 20; 122(10):1167-72. PubMed ID: 19493465
    [Abstract] [Full Text] [Related]

  • 4. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
    Zou J, Yin F, Wang Q, Zhang W, Li L.
    Int J Clin Exp Pathol; 2015 May 20; 8(6):6847-58. PubMed ID: 26261572
    [Abstract] [Full Text] [Related]

  • 5. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.
    Gao Y, Liu X, Li T, Wei L, Yang A, Lu Y, Zhang J, Li L, Wang S, Yin F.
    Oncol Rep; 2017 May 20; 37(5):3084-3092. PubMed ID: 28350120
    [Abstract] [Full Text] [Related]

  • 6. Characterization of microRNA expression in serous ovarian carcinoma.
    Li Y, Yao L, Liu F, Hong J, Chen L, Zhang B, Zhang W.
    Int J Mol Med; 2014 Aug 20; 34(2):491-8. PubMed ID: 24939816
    [Abstract] [Full Text] [Related]

  • 7. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
    Konno R.
    Hum Cell; 2001 Dec 20; 14(4):261-6. PubMed ID: 11925926
    [Abstract] [Full Text] [Related]

  • 8. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.
    Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, Macgregor PF, Rosen B.
    Oncol Rep; 2007 Dec 20; 18(6):1347-56. PubMed ID: 17982616
    [Abstract] [Full Text] [Related]

  • 9. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.
    Biomed Pharmacother; 2009 Sep 20; 63(8):553-60. PubMed ID: 18571892
    [Abstract] [Full Text] [Related]

  • 10. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
    Januchowski R, Zawierucha P, Ruciński M, Zabel M.
    Oncol Rep; 2014 Nov 20; 32(5):1981-90. PubMed ID: 25199881
    [Abstract] [Full Text] [Related]

  • 11. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD.
    Gynecol Oncol; 2006 Nov 20; 103(2):405-16. PubMed ID: 16725184
    [Abstract] [Full Text] [Related]

  • 12. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
    Wu YH, Chang TH, Huang YF, Huang HD, Chou CY.
    Oncogene; 2014 Jun 26; 33(26):3432-40. PubMed ID: 23934190
    [Abstract] [Full Text] [Related]

  • 13. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
    Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):690-700. PubMed ID: 16467078
    [Abstract] [Full Text] [Related]

  • 14. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A, Jurisica I, Letarte M, Shaw PA, Parkes RK, Zhang X, Evangelou A, Rosen B, Murphy KJ, Brown TJ.
    Oncogene; 2007 Jan 11; 26(2):198-214. PubMed ID: 16832351
    [Abstract] [Full Text] [Related]

  • 15. Screening of the metastasis-associated genes by gene chip in high metastatic human ovarian cancer cell lines.
    Xu S, Mou H, Gu L, Su D, Zhu C, Liu X.
    J Genet Genomics; 2007 Jul 11; 34(7):581-90. PubMed ID: 17643943
    [Abstract] [Full Text] [Related]

  • 16. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer.
    Li J, Zhang Y, Gao Y, Cui Y, Liu H, Li M, Tian Y.
    Oncol Rep; 2014 Sep 11; 32(3):979-88. PubMed ID: 24968817
    [Abstract] [Full Text] [Related]

  • 17. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.
    Clin Cancer Res; 2005 Aug 15; 11(16):6030-9. PubMed ID: 16115948
    [Abstract] [Full Text] [Related]

  • 18. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.
    Sawiris GP, Sherman-Baust CA, Becker KG, Cheadle C, Teichberg D, Morin PJ.
    Cancer Res; 2002 May 15; 62(10):2923-8. PubMed ID: 12019173
    [Abstract] [Full Text] [Related]

  • 19. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
    Zhan SJ, Liu B, Linghu H.
    Oncol Rep; 2018 Jun 15; 39(6):2653-2663. PubMed ID: 29693178
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.
    Liu X, Zou J, Su J, Lu Y, Zhang J, Li L, Yin F.
    Int J Oncol; 2016 Jan 15; 48(1):243-52. PubMed ID: 26647723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.